Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anitocabtagene autoleucel versus standard of care for relapsed/refractory multiple myeloma
NL-OMON60909Phase 3Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- May 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Anitocabtagene autoleucel with Standard of care therapy (2 arms). Primary endpoints: Progression-free survival and MRD-negative complete response rate at 9 months. Started May 2025; status: active, not recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60909.